Journal article
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy
Abstract
AIMS: Guidelines recommend extended dual pathway inhibition (DPI) with aspirin and rivaroxaban in patients with chronic coronary syndrome (CCS) at high ischaemic risk. The CHADS-P2A2RC score improves risk prediction and enables antithrombotic treatment allocation in these patients. This study evaluated the net clinical benefit of DPI treatment according to baseline risk as classified by the CHADS-P2A2RC score in patients with CCS included in …
Authors
Würtz M; Olesen KKW; Bhatt DL; Yusuf S; Muehlhofer E; Eikelboom JW; Maeng M
Journal
European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 10, No. 3, pp. 201–209
Publisher
Oxford University Press (OUP)
Publication Date
May 4, 2024
DOI
10.1093/ehjcvp/pvae017
ISSN
2055-6837